Path Forward For Viridian’s IGF-1R Antibody In Chronic TED Raises Questions

Pivotal Trial Amendment Controversial

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

The US firm’s potential rival to Horizon’s Tepezza, VRDN-001, showed positive signals in a small group of patients with chronic thyroid eye disease in a Phase I/II trial, but its decision to drop one planned dosing regimen from an upcoming pivotal trial has put off some analysts.  

bulging eye
TED Causes Double Vision, Pain And Proptosis (Bulging Eyes) • Source: Shutterstock

Key Takeaways:

  • VRDN-001 was associated with a mean 2.0mm reduction in proptosis as measured by MRI.

Viridian Therapeutics, Inc.’s anti-IGF-1R monoclonal antibody candidate, VRDN-001, has garnered attention after promising proof-of-concept data in chronic thyroid eye disease (TED) but not all of it is positive, with questions raised about a change to the design of its pivotal program.

TED, also known as Graves’ disease, is a debilitating rare disorder characterized by inflammation within the orbit of the eye,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D